Announced Wed, 7 Oct, 2026 · 18:47 IST

Compliance certificates filed for quarter ended Sept 30, 2026

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.2%Reaction day

₹25.55

prior close

₹24.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.8%+1.6% vs market

Pharmaceuticals peers, median of 172sector-2.5%+1.3% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+13.9

10m

+12.0

15m

+12.0

30m

+12.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.2-2.8+1.6-2.5+1.3

Next day

+3.3-2.5+5.8-2.6+5.9

-0.2-1.7+1.4-2.5+2.3

-2.2-1.5-0.7-2.6+0.4

-4.1-0.8-3.3-2.5-1.6

-8.5-2.4-6.1-3.2-5.4

-2.6-3.4+0.8-4.4+1.8

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs filed a Regulation 74(5) certificate from its registrar Adroit Corporate Services confirming that shares sent for dematerialization in the quarter ended 30 September 2026 were processed, listed, and the depositories recorded as owners within 15 days. The company also submitted a non-applicability certificate under Regulation 57(5). This is routine SEBI compliance, not a material event.

Likely market impact

Routine regulatory compliance filing. No material impact on shareholders or stock price.